Saturday 17 October 2026
Export ALDX’s income statement to Excel — free account
Aldeyra Therapeutics, Inc.
ALDX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.8%, free cash flow grew 46.1% and total debt rose 1.33%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.70
0.04
−5.41%
Follow ALDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (49.48%) | (51.76%) | (58.73%) | (64.31%) |
+8 more TTM periods Free account |
|
| (34.80%) | (34.28%) | (38.32%) | (44.27%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(61.08%) | (65.25%) | (76.97%) | (88.19%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.37) | (0.43) | (0.56) | (0.67) | |
Free Cash Flow |
(22.04) | (25.99) | (33.35) | (40.08) | |
Capital Expenditures |
(0.02) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(26.57%) | (21.22%) | (25.74%) | (28.68%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(16.95) | (15.01) | (18.51) | (23.77) | |
Operating CF/Net income |
0.96 | 0.95 | 0.99 | 0.93 | |
Depreciation/Fixed assets |
(2.18) | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.52 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.37) | (0.43) | (0.56) | (0.67) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates